Igyxos secures a seasoned govt to assist advance IGX12, a primary at school remedy for each female and male infertility
PARIS, FRANCE, October 16, 2023 /EINPresswire.com/ — Igyxos, a privately owned biopharmaceutical firm growing breakthrough therapies for infertility and devoted to enhancing sufferers’ outcomes, is delighted to announce the appointment of Emmanuel Dulac as its new CEO. Emmanuel brings a wealth of expertise and experience to Igyxos, having held quite a few management positions within the pharmaceutical and biotechnology business.
Emmanuel’s distinguished profession spans over 25 years, throughout which he has efficiently led and remodeled companies within the international biotechnology sector. Previous to taking the lead at Igyxos, Emmanuel served as the CEO of Zealand Pharma, CCO of Alnylam and Head of Uncommon Ailments at Shire, the place he performed a pivotal function in driving innovation and enterprise progress.
With a powerful observe document of strategic imaginative and prescient and execution, Emmanuel is poised to information Igyxos into its subsequent section of improvement and enlargement. His management abilities, mixed together with his deep understanding of biotechnology, make him the perfect alternative to steer Igyxos via the evolving challenges and alternatives of the business.
Commenting on his appointment, Emmanuel mentioned, “I’m honored to affix Igyxos as its CEO to steer an distinctive workforce of gifted people and thrilled to assist advance a brand new promising remedy for infertile {couples}. Igyxos workforce has constructed a stable fame in analysis and may satisfaction themselves in having found a real novel remedy for infertile {couples}, first within the final 35 years, that seems from animal fashions to work in males, females, alone or synergistically with current ones. I look ahead to drive continued success within the clinics.”
As the brand new CEO, Emmanuel will concentrate on accelerating Igyxos’s progress trajectory within the clinics, fostering strategic partnerships, and proceed to drive improvements throughout its product portfolio. His international market expertise, customer-centric strategy and dedication to excellence align completely with Igyxos’s values and mission.
This announcement follows a sequence of current successes for Igyxos lead product IGX12, first at school mAb, exhibiting sturdy response in each female and male, alone or together with FSH and in varied animal fashions. The appointment of Emmanuel Dulac alerts Igyxos’s dedication to construct on its momentum and obtain even higher success.
About Igyxos: Igyxos Biotherapeutics, a French biotechnology firm, is devoted to addressing the rising international want for improved infertility options via novel therapeutics that make remedy more practical and environment friendly for women and men. To remodel infertility remedy and improve sufferers’ outcomes, we’re pioneering the primary monoclonal antibody (mAb)-based remedy that binds to and enhances the exercise of gonadotropins – hormones concerned in replica – and considerably improves their exercise for infertility therapies. Main traders in Igyxos are UI investissement, Bpifrance and Go Capital.
For inquiries or additional info, please go to https://www.igyxos.com/ or contact: Élodie Kara, elodie.kara@igyxos.com
Élodie Kara
Igyxos
+33 2 47 42 79 38
e-mail us right here
